Application and Efficacy Evaluation of Clinical Pharmacist-Involved MDT in XDR Bacterial Infection Treatment

DOI: https://doi.org/10.62517/jmhs.202605123

Author(s)

Jin Wang

Affiliation(s)

Army 958 Hospital, Chongqing, China

Abstract

This study investigates the core value of a clinical pharmacist-involved multidisciplinary team (MDT) model for treating extensively drug-resistant (XDR) bacterial infections, and verifies its efficacy in optimizing therapy, improving clinical outcomes and curbing antimicrobial resistance to support standardized clinical practice. A retrospective cohort of 226 XDR-infected patients (January 2023–June 2025) was 1:1 propensity-matched into MDT (n=113) and conventional single-discipline treatment (n=113) groups. The MDT group achieved significantly higher clinical cure (82.3% vs 59.3%, P<0.001) and bacterial eradication rates (78.8% vs 53.1%, P<0.001), lower 30-day mortality (9.7% vs 24.8%, P=0.002) and shorter hospital stay (14.2±3.8 vs 21.6±5.2 days, P<0.001). It also had fewer antimicrobial-related adverse events (6.2% vs 18.6%, P=0.003), 32.6% lower antimicrobial costs, 28.9% lower total medical costs, and a higher appropriate antimicrobial use rate (94.7% vs 67.3%, P<0.001). Subgroup analyses confirmed consistent benefits across CRE, MRSA and VRE infections, with the most marked mortality reduction (21.3%) in critically ill patients (APACHE Ⅱ≥25). Clinical pharmacists optimized antimicrobials based on susceptibility and PK/PD principles, designed AI-assisted individualized dosing, monitored adverse reactions and provided antimicrobial stewardship. This MDT model significantly improves XDR infection outcomes, promotes rational antimicrobial use, reduces medical costs and slows resistance development. It is a practical, efficient strategy worthy of global promotion, especially in resource-limited regions.

Keywords

Extensively Drug-Resistant Bacteria; Multidisciplinary Team; Clinical Pharmacist; Antimicrobial Stewardship; Infection Treatment; Efficacy Evaluation

References

[1] World Health Organization. Global action plan on antimicrobial resistance Geneva: WHO, 2021. [2] Chinese Society of Infectious Diseases, Chinese Medical Association. Expert Consensus on the Diagnosis and Treatment of Extensively Drug-Resistant Bacterial Infections (2024 Edition) Chinese Journal of Infectious Diseases, 2024, 42(5): 289-302. [3] National Health Commission of the People's Republic of China. Measures for the Administration of Clinical Application of Antimicrobials (2023 Revised Edition) 2023. [4] Tan J, Li Y, Wang H, et al. Multidisciplinary team approach improves outcomes of carbapenem-resistant Enterobacterales infections: a systematic review and meta-analysis International Journal of Antimicrobial Agents, 2023, 62(4): 106689. [5] Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (34th ed) CLSI, 2024. [6] Infectious Diseases Professional Committee of China Medicine Education Association. Expert Consensus on Clinical Application of Carbapenem Antimicrobials (2024 Edition) Chinese Journal of Infection Control, 2024, 23(3): 281-290. [7] Liu C, Zhang Y, Chen W, et al. Artificial intelligence-based pharmacokinetic model for vancomycin therapeutic drug monitoring in critically ill patients Computational Biology and Chemistry, 2024, 109: 107785. [8] Chinese Society of Anesthesiologists. Expert Consensus on General Anesthesia Management for High-Risk Adults with Regurgitation and Aspiration (2025 Edition) Journal of Clinical Anesthesiology, 2025, 41(9): 901-907. [9] Huang YG, Deng XM. Modern Anesthesiology (6th Edition) Beijing: People's Medical Publishing House, 2024: 896-903. [10] Zhang MZ, Li ST. Anesthetic Ultrasonography Shanghai: Shanghai Science and Technology Press, 2023: 156-168.